Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENJAMIN R COOK

Allopathic & Osteopathic Physicians Family Medicine

NPI
1679998975
CMS profile
610134
Location
JEFFERSON CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,210.85

136 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,210.85 136

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENJAMIN R COOK

NPI 1679998975 · CMS profile ID 610134

Allopathic & Osteopathic Physicians / Family Medicine

JEFFERSON CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679998975?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENJAMIN R COOK, NPI 1679998975, CMS profile ID 610134. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679998975?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BENJAMIN R COOK, NPI 1679998975, CMS profile ID 610134. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679998975?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BENJAMIN R COOK, NPI 1679998975, CMS profile ID 610134, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 136 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1679998975?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

136 matching records · $2,210.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 136 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 136.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $18.1707/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201690413 CMS
Novo Nordisk Inc $4.1007/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188743932 CMS
Novo Nordisk Inc $8.8607/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188804618 CMS
PFIZER INC. $15.9907/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229025343 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $16.0007/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241281673 CMS
Amgen Inc. $12.9107/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227189930 CMS
ABBVIE INC. $11.4607/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201690411 CMS
Lilly USA, LLC $16.2807/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186526531 CMS
ABBVIE INC. $25.6207/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201690409 CMS
ABBVIE INC. $19.8007/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201690407 CMS
PFIZER INC. $24.2007/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231625535 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.6807/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222953928 CMS
ABBVIE INC. $16.3007/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201690405 CMS
PFIZER INC. $15.8607/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231610466 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $20.0006/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241281670 CMS
Phathom Pharmaceuticals, Inc. $11.6106/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219363192 CMS
Amgen Inc. $13.7206/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227189918 CMS
Edwards Lifesciences Corporation $27.4406/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225231575 CMS
PFIZER INC. $20.1806/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231281026 CMS
PFIZER INC. $15.6006/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231659896 CMS
Exact Sciences Corporation $17.1906/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235533149 CMS
VERTEX PHARMACEUTICALS INCORPORATED $21.3206/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213890399 CMS
Lilly USA, LLC $20.5806/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186476171 CMS
PFIZER INC. $17.5806/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228802582 CMS
ABBVIE INC. $21.8906/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201690403 CMS
AstraZeneca Pharmaceuticals LP $17.8706/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207233580 CMS
Phathom Pharmaceuticals, Inc. $11.3805/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219363180 CMS
Novo Nordisk Inc $13.8805/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188703533 CMS
PFIZER INC. $7.0405/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228966368 CMS
Amgen Inc. $8.6205/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227189928 CMS
VERTEX PHARMACEUTICALS INCORPORATED $68.4005/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213940534 CMS
Dexcom, Inc. $23.6905/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250473053 CMS
PFIZER INC. $17.5805/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230046677 CMS
Novo Nordisk Inc $18.7505/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188683507 CMS
ABBVIE INC. $12.9005/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201690401 CMS
AstraZeneca Pharmaceuticals LP $22.2705/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206909554 CMS
PFIZER INC. $12.3705/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231306619 CMS
PFIZER INC. $3.5704/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229063329 CMS
Amgen Inc. $13.7504/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227189914 CMS
Novo Nordisk Inc $13.4004/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188866761 CMS
Phathom Pharmaceuticals, Inc. $13.7604/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219363178 CMS
VERTEX PHARMACEUTICALS INCORPORATED $22.9104/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213835776 CMS
PFIZER INC. $19.8204/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231406049 CMS
Dexcom, Inc. $25.7404/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250473051 CMS
ABBVIE INC. $16.0604/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201690399 CMS
Novo Nordisk Inc $17.1704/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188828270 CMS
AstraZeneca Pharmaceuticals LP $20.1704/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207289852 CMS
PFIZER INC. $18.4604/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231601520 CMS
PFIZER INC. $16.5304/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228859514 CMS
Abbott Laboratories $137.1104/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240918287 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,139.98 79
PY2020 $311.85 16
PY2021 $1,058.05 78
PY2022 $1,781.61 126
PY2023 $1,776.35 132
PY2024 $2,061.57 123
PY2025 $2,210.85 136

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,640,350.86 112
PY2024 Principal investigator $171,685.46 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

112 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bavarian Nordic A/S $6,635.75 12/24/2025 Non-covered Recipient Entity
QCare Site Services Inc.
WEV-MVA-002 No dispute reported 06/30/2026 1250214456
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $764.31 12/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279302
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.00 12/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,971.00 12/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279306
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $552.00 12/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279316
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,097.60 12/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279318
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,865.00 12/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279320
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,357.92 12/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184279322
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,867.46 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,350.00 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,979.00 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,872.02 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,604.49 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269505
Principal investigator 1 Bavarian Nordic A/S $2,119.00 12/03/2025 Non-covered Recipient Entity
QCare Site Services Inc.
WEV-MVA-002 No dispute reported 06/30/2026 1250214454
Principal investigator 1 Bavarian Nordic A/S $4,970.40 11/25/2025 Non-covered Recipient Entity
QCare Site Services Inc.
WEV-MVA-002 No dispute reported 06/30/2026 1250214452
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,319.61 11/25/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184264369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,653.61 11/20/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,178.00 11/20/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263351
Principal investigator 1 Bavarian Nordic A/S $728.00 11/14/2025 Non-covered Recipient Entity
QCare Site Services Inc.
WEV-MVA-002 No dispute reported 06/30/2026 1250214450
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,362.57 11/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184260981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,003.00 11/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184260983
Principal investigator 1 Bavarian Nordic A/S $2,725.55 11/03/2025 Non-covered Recipient Entity
QCare Site Services Inc.
WEV-MVA-002 No dispute reported 06/30/2026 1250214448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,235.69 10/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24,721.51 10/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252830
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,780.20 10/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,431.68 10/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,070.00 10/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $952.20 10/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33,567.06 10/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252848
Principal investigator 1 Bavarian Nordic A/S $9,517.00 10/17/2025 Non-covered Recipient Entity
QCare Site Services Inc.
WEV-MVA-002 No dispute reported 06/30/2026 1250214446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,228.26 10/16/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250875
Principal investigator 1 Bavarian Nordic A/S $40,036.80 10/10/2025 Non-covered Recipient Entity
QCare Site Services Inc.
WEV-MVA-002 No dispute reported 06/30/2026 1250214444
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30,212.00 10/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,370.75 10/03/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,891.39 09/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,557.00 09/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $284,999.98 09/16/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184237550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,121.79 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236730
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,014.30 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $634.80 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $358.80 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,898.00 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236746
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,312.00 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236748
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,210.00 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $317.40 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.70 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $414.00 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236756
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,806.92 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $89.70 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,936.00 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,863.36 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,380.36 09/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,646.78 08/26/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $688.00 08/26/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,210.00 08/26/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230503
Principal investigator 1 Bavarian Nordic A/S $47,054.45 08/25/2025 Non-covered Recipient Entity
QCare Site Services Inc.
WEV-MVA-002 No dispute reported 06/30/2026 1250214442
Principal investigator 1 Bavarian Nordic A/S $141,754.25 08/18/2025 Non-covered Recipient Entity
QCare Site Services Inc.
WEV-MVA-002 No dispute reported 06/30/2026 1250214406
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,690.18 08/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,311.46 08/07/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,354.86 07/31/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222990
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,300.00 07/31/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222996
Principal investigator 1 Bavarian Nordic A/S $522.00 07/28/2025 Non-covered Recipient Entity
QCare Site Services Inc.
WEV-MVA-002 No dispute reported 06/30/2026 1250214404
Principal investigator 1 Bavarian Nordic A/S $245,944.55 07/23/2025 Non-covered Recipient Entity
QCare Site Services Inc.
WEV-MVA-002 No dispute reported 06/30/2026 1250214402
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,978.30 07/22/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,354.86 07/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217272
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,354.86 07/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214560
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,721.50 07/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184213043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,800.00 07/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184213045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 07/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184213047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,978.30 06/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209312
Principal investigator 1 Bavarian Nordic A/S $594.00 06/13/2025 Non-covered Recipient Entity
QCare Site Services Inc.
WEV-MVA-002 No dispute reported 06/30/2026 1250214400
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,738.24 06/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,743.20 06/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55,890.00 06/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,080.00 06/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,598.00 06/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,800.48 06/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,628.56 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184199035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,628.56 05/22/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,366.64 05/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39,744.00 05/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,592.00 05/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,948.44 05/08/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184193823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,149.20 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190695
Principal investigator 1 Bavarian Nordic A/S $9,863.00 04/25/2025 Non-covered Recipient Entity
QCare Site Services Inc.
WEV-MVA-002 No dispute reported 06/30/2026 1250214398
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,825.80 04/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,945.11 04/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183346
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,048.23 04/08/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184181986
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,683.63 04/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,005.13 03/25/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,039.07 03/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174376
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $138.00 03/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174390
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,770.75 03/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170934
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $207.00 03/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170938
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,948.44 03/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,056.82 02/25/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,602.50 02/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154442
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,706.80 02/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,037.50 02/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154450
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,258.16 02/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154452
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,898.00 02/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154454
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,693.00 02/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154456
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,465.57 02/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,410.00 02/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152638
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,500.00 02/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152640
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,391.00 02/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152642
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,838.04 01/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149982
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $276.00 01/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149986
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,198.55 01/21/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,854.49 01/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,226.25 01/07/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184146050
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,028.41 01/07/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184146052